Navigation Links
Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
Date:7/28/2009

CINCINNATI, July 28 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the realignment of its C-suite to strengthen its competitive position and position the Company for continued growth as a top-tier global CRO. The creation of a new Chief Administrative Officer (CAO) role within Kendle's C-suite and executive leadership team as part of this realignment provides dedicated leadership for strategic technology and infrastructure enhancement initiatives to drive down overhead and deliver increased innovation, productivity and organizational efficiency, strengthening the Company's ability to deliver strategic outsourcing solutions for its global biopharmaceutical customers.

Assuming the new leadership role of Executive Vice President and CAO is Kendle's current Chief Operating Officer (COO), Christopher C. Bergen. Mr. Bergen is a co-founder of Kendle, and served as President and Chief Operating Officer from the Company's founding in June 1981 until April 2008 and as Chief Operating Officer from April 2008 until July 2009. He has more than 30 years of experience in the clinical research industry, with demonstrated expertise in the design and implementation of innovative technology solutions to enhance clinical trial delivery and organizational efficiency. As COO Mr. Bergen has provided executive leadership for Kendle's ERP initiative, the largest initiative in the Company's history, which will yield significant benefits for the organization and its customers, including streamlined global processes, enhanced organizational efficiency and real-time access to clinical trial data to facilitate efficient project management. Kendle currently is in the final stages of implementing the financial components of its ERP.

"As we move forward and position Kendle to compete for higher-level strategic outsourcing opportunities our infrastructure and ability to deliver on a global scale have never been more important," said Candace Kendle, PharmD, Chairman and Chief Executive Officer. "This new executive leadership role and the appointment of our most senior leader to fill it demonstrates Kendle's continued focus on the key business drivers that will support our future growth and meet the strategic outsourcing needs of our customers."

The creation of the CAO role and the appointment of Mr. Bergen complement other recent moves by Kendle to strengthen its executive leadership team. In conjunction with the appointment of Mr. Bergen, Kendle today announced the appointment of former Quintiles executive and 20-year industry veteran Stephen Cutler, PhD, as its new Senior Vice President and COO, providing global leadership for the Company's worldwide Late Stage operations.

In addition, reflecting Kendle's increasing focus on strategic customer relationships, Simon Higginbotham is adding the Chief Marketing Officer (CMO) role to his leadership of the Company's Early Stage business, assuming the title of Senior Vice President and CMO effective immediately.

Additional moves to enhance key strategic roles within the Company's C-suite in recent months include the appointments of Jarrod Pontius as Vice President, Chief Legal Officer and Secretary and the appointment of Keith Cheesman as Senior Vice President and Chief Financial Officer.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
2. Kendle Names Jarrod Pontius Chief Legal Officer
3. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
4. Kendle Announces First Quarter 2009 Results
5. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
6. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
7. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
8. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
9. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
10. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
11. Kendle to Present at the 2008 Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development and commercialization ... at the 18 th Annual BIO CEO & ... a.m. EST in New York, NY . ... will provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
Breaking Biology Technology:
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... Jan. 11, 2016  higi, the leading retail ... retail locations, web and mobile, today announced it ... from existing investors. --> ... to further innovate higi,s health platform – its ... portal – including expanding services and programs to ...
Breaking Biology News(10 mins):